Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2459 publications

A Detailed Assessment of an Electrocardiogram During an Arrhythmic Attack in a Patient Receiving Afatinib.

A Detailed Assessment of an Electrocardiogram During an Arrhythmic Attack in a Patient Receiving Afatinib.

Journal: Internal medicine (Tokyo, Japan)
Published: October 08, 2025

Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.

Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.

Journal: Future science OA
Published: September 24, 2025

Sunvozertinib (Zegfrovy) for NSCLC.

Sunvozertinib (Zegfrovy) for NSCLC.

Journal: The Medical letter on drugs and therapeutics
Published: September 09, 2025

Successful Salvage Treatment With Afatinib and Anti-PD-1 Combined Chemotherapy in a Pediatric Patient With Relapsed Cellular-Type Congenital Mesoblastic Nephroma Harboring an EGFR-KDD Mutation.

Successful Salvage Treatment With Afatinib and Anti-PD-1 Combined Chemotherapy in a Pediatric Patient With Relapsed Cellular-Type Congenital Mesoblastic Nephroma Harboring an EGFR-KDD Mutation.

Journal: Pediatric blood & cancer
Published: August 14, 2025

Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Journal: Internal medicine (Tokyo, Japan)
Published: August 13, 2025

Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Journal: Internal medicine (Tokyo, Japan)
Published: August 13, 2025

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

Journal: Cells
Published: July 30, 2025

Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 24, 2025

Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 24, 2025

Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 24, 2025

Sensitive analysis of tyrosine kinase inhibitors in plasma using polypropylene fabric-solid phase extraction combined with liquid chromatography-tandem mass spectrometry.

Sensitive analysis of tyrosine kinase inhibitors in plasma using polypropylene fabric-solid phase extraction combined with liquid chromatography-tandem mass spectrometry.

Journal: Journal of chromatography. A
Published: July 17, 2025

An Extremely Rare Case of Pneumatosis Intestinalis Likely Induced by Afatinib Treatment for EGFR-mutated Stage IV Non-small Cell Lung Cancer.

An Extremely Rare Case of Pneumatosis Intestinalis Likely Induced by Afatinib Treatment for EGFR-mutated Stage IV Non-small Cell Lung Cancer.

Journal: Annali italiani di chirurgia
Published: July 16, 2025
Showing 1-12 of 2,459

Last Updated: 10/31/2025